Ra Medical Systems (RMED) Stock Price
Ra Medical Systems Price
Revenue at Ra Medical Systems has contracted by 63.6% per year over the past 6 years to 14,000.00 USD. For Ra Medical Systems, the net margin of -191,892.9% is down versus -492.5% a few years ago. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
Ra Medical Systems stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Ra Medical Systems over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Ra Medical Systems stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Ra Medical Systems's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Ra Medical Systems Price |
|---|
Ra Medical Systems Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Ra Medical Systems Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.01 | 0.01 | – | – | – | – | – | 0.01 | 0.02 | 2.06 |
| – | – | 20.00 | -83.33 | – | – | – | – | 700.00 | 162.50 | 9,685.71 |
| 40.00 | 20.00 | 33.33 | -200.00 | – | – | – | -100.00 | -12.50 | -4.76 | -0.05 |
| 2.00 | 1.00 | 2.00 | -2.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 |
| -4.00 | -17.00 | -31.00 | -52.00 | -35.00 | -29.00 | -22.00 | -72.00 | -3.00 | 4.00 | -21.00 |
| -80.00 | -340.00 | -516.67 | -5,200.00 | – | – | – | -7,200.00 | -37.50 | 19.05 | -1.02 |
| – | -0.02 | -0.03 | -0.06 | -0.04 | -0.03 | -0.03 | -0.67 | -0.02 | 0.02 | -1.44 |
| – | 325.00 | 76.47 | 86.67 | -35.71 | -30.56 | 4.00 | 2,465.38 | -97.45 | -194.12 | -9,081.25 |
| 0.46 | 0.46 | 0.37 | 0.01 | 0.03 | 0.10 | 1.03 | 1.03 | 1.03 | 1.03 | 1.03 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Ra Medical Systems generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Ra Medical Systems retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Ra Medical Systems's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Ra Medical Systems has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Ra Medical Systems's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Ra Medical Systems stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Ra Medical Systems Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Ra Medical Systems business model & stock analysis
Ra Medical Systems SWOT Analysis
Strengths
One of Ra Medical Systems Inc's key strengths is its innovative and advanced medical technology, which enables the company to offer effective and minimally invasive treatment solutions to patients.
The company's strong research and development capabilities allow it to continuously improve its products and stay ahead of competitors in the market.
Ra Medical Systems Inc has established a solid reputation within the medical industry, which enhances its brand image and fosters trust among healthcare professionals.
Weaknesses
One of the weaknesses Ra Medical Systems Inc faces is its limited market presence, particularly in comparison to larger and more established competitors.
The company may face challenges in terms of scaling up its operations and distribution network to meet increasing demand.
Ra Medical Systems Inc lacks the financial resources of larger competitors, which could limit its ability to invest in marketing and expanding market reach.
Opportunities
The growing demand for minimally invasive treatment options presents an opportunity for Ra Medical Systems Inc to expand its market share.
As healthcare regulations and policies evolve, the company can capitalize on government initiatives that promote the adoption of advanced medical technologies.
Expansion into new geographical markets, both domestically and internationally, can significantly increase the company's revenue and customer base.
Threats
Intense competition within the medical technology industry poses a threat to Ra Medical Systems Inc, as larger and more established companies have greater resources and market reach.
Changing reimbursement policies by insurance providers and government healthcare programs can negatively impact the company's profitability and market access.
Rapid technological advancements in the industry could render Ra Medical Systems Inc's current products obsolete or less competitive.
Ra Medical Systems Segments
Ra Medical Systems Revenue by Segment (1/2)
3 Years
5 Years
Max
Details
Ra Medical Systems Revenue by Segment (2/2)
Max
Details
Ra Medical Systems Revenue by Region
Max
Details
Ra Medical Systems Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Ra Medical Systems historical P/E ratio, EBIT multiple, and P/S ratio
Ra Medical Systems annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Ra Medical Systems shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Ra Medical Systems stock splits
Current Ra Medical Systems forecasts and price targets in August 2026
Analyst Price Targets 2026Ra Medical Systems Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 5/31/2024 | -0.14USD | - | 1.24 MUSD | - | 2024 Q1 |
| 8/14/2023 | -0.10USD | - | 0.00USD | - | 2023 Q2 |
| 11/14/2022 | -8.16USD | - | 0.00USD | - | 2022 Q3 |
Ra Medical Systems shareholder structure
| % | Name |
|---|---|
0.03382% | |
0.03136% | |
0.02839% | |
0.02471% | |
0.01478% | |
0.00948% |
Frequently asked questions about Ra Medical Systems
Ra Medical Systems Inc. operates as a medical device company that develops and markets excimer lasers for use in the treatment of various dermatological and cardiovascular conditions. The business model of Ra Medical Systems Inc. revolves around providing innovative laser technology solutions to healthcare professionals and institutions worldwide. With a focus on delivering safe, effective, and cost-efficient treatments, the company aims to address the needs of patients suffering from chronic skin diseases and cardiovascular disorders. By developing cutting-edge laser systems and partnering with healthcare providers, Ra Medical Systems Inc. strives to improve medical outcomes and enhance patient care within the medical community.
Ra Medical Systems Inc is primarily active in the medical equipment industry.
The main competitors of Ra Medical Systems Inc in the market include companies such as AngioDynamics, Inc., AngioSculpt, Biolitec AG, Cardiovascular Systems, Inc., and Medtronic Plc.
Ra Medical Systems Inc is a medical device company based in California. Established in 2002, Ra Medical Systems specializes in the development, manufacturing, and commercialization of excimer lasers for the treatment of a wide range of dermatologic and cardiovascular conditions. The company's flagship product, Pharos, is an advanced excimer laser system designed for the therapy of psoriasis, vitiligo, and other skin disorders. Ra Medical Systems has a strong commitment to innovation and patient safety, continuously striving to provide effective and minimally invasive treatment options for patients worldwide. With its cutting-edge technology, Ra Medical Systems Inc has emerged as a prominent player in the medical industry.
Ra Medical Systems Inc, a leading medical technology company, has achieved several significant milestones. Firstly, the company developed and launched the ground-breaking excimer laser system, Pharos, which revolutionized the treatment of chronic skin diseases with its targeted UVB phototherapy. Secondly, Ra Medical Systems received clearance from the U.S. FDA for its excimer laser system in 2004, opening new avenues for providing effective and safe treatment options. Moreover, in 2017, the company achieved ISO 13485 certification, showcasing its commitment to maintaining high-quality standards in the manufacturing of medical devices. These milestones highlight Ra Medical Systems Inc's commitment to innovation and improving patient outcomes in the field of dermatology.
Ra Medical Systems Inc is primarily present in the United States.
Ra Medical Systems Inc represents values of innovation, quality, and patient care. The company is committed to delivering advanced medical technologies that improve the lives of patients worldwide. With a strong corporate philosophy centered on enhancing treatment options, Ra Medical Systems Inc focuses on developing and commercializing innovative solutions for vascular and dermatological diseases. By prioritizing research and development, the company aims to provide physicians with effective, safe, and minimally invasive treatment options. Through its dedication to excellence and commitment to patient outcomes, Ra Medical Systems Inc strives to be a leader in the field of medical technology, delivering cutting-edge solutions that make a meaningful difference in people's lives.
7 analysts currently rate the Ra Medical Systems stock: 6 recommend buying, 1 holding and 0 selling.
Ra Medical Systems Inc is a US-American company specialized in the development and marketing of innovative technologies for the treatment of vascular diseases. The company has been active since 2002 and is headquartered in Carlsbad, California. Its product range includes the DABRA system and the Pharos system. The DABRA system is a commercially available laser ablation system for the treatment of peripheral atherosclerotic lesions in the arteries. The Pharos system is a non-invasive laser device for the treatment of cutaneous lesions such as psoriasis or vitiligo. The company earns its money through the sale of its medical devices to private clinics and medical facilities domestically and internationally. It also generates revenue through ongoing maintenance and support of its devices. Ra Medical Systems operates its own research and development department specializing in the development of new technologies for the diagnosis and treatment of vascular diseases. The company focuses on developing technologies that offer higher effectiveness and lower risk for patients compared to conventional methods. With a strong distribution network and a presence at international trade shows, Ra Medical Systems is well-positioned to continue operating successfully in the market.
The revenue cannot currently be calculated for Ra Medical Systems.
The profit cannot currently be calculated for Ra Medical Systems.
The P/E ratio cannot be calculated for Ra Medical Systems at the moment.
The P/S cannot be calculated for Ra Medical Systems currently.
The Eulerpool Quality Score for Ra Medical Systems is 2/10.
The ISIN of Ra Medical Systems is US74933X2036. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Ra Medical Systems is A2QJCG. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Ra Medical Systems is RMED. The ticker symbol is used to trade Ra Medical Systems shares on the stock exchange.
Ra Medical Systems is assigned to the 'Health' sector.
The dividends of Ra Medical Systems are distributed in USD.
Ra Medical Systems stock
Ra Medical Systems Peer Group
All fundamentals and in-depth analysis of Ra Medical Systems
Our stock analysis for Ra Medical Systems stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ra Medical Systems. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.